On February 18, 2025 ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing therapies that boost the immune system to treat cancer and extend patients’ lives, reported that it will host a virtual Research and Development (R&D) Day webcast on Wednesday, March 5, 2025, at 6:00 a.m. PT/9:00 a.m. ET (Press release, ALX Oncology, FEB 18, 2025, View Source [SID1234650328]). The virtual webcast event will focus on information and updates related to the company’s pipeline, lead investigational CD47-blocker evorpacept, as well as business and financial updates.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
R&D Day Webcast Information
The ALX Oncology virtual R&D Day will be webcast live and a replay will be available after the event by visiting the "Investors" section of ALX Oncology’s website and selecting "Events and Presentations."
Date & Time: Wednesday, March 5, 2025, 6:00 a.m. PT/9:00 a.m. ET
Webcast Access: View Source